logo-loader
viewUrigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

Urigen Pharmaceuticals, Inc CEO Dan Vickery sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The privately-held company specializes in non-oncological urology treatments.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Standard Uranium shares details of their project as they...

Standard Uranium (CVE: STND) President and CEO Jon Bey sat down with Steve Darling from Proactive Vancouver to discuss details about uranium exploration company that plan to take public very soon.  Bey telling Proactive about their project in the Athabasca Basin and also abut their...

1 hour, 53 minutes ago

2 min read